content: <HTML>
  <HEAD>
  <TITLE>
  </TITLE>
  </HEAD>
  <BODY>
                                                       6
  
  
  
  
  
  
  
  
  
  
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SECURITIES
  AND EXCHANGE COMMISSION</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>WASHINGTON,
  D.C. 20549</FONT></H1>
  
  <HR SIZE=1 NOSHADE WIDTH=15% ALIGN=CENTER>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>FORM 8-K</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT
  REPORTPURSUANT <BR>TO SECTION 13 OR 15(d) OF THE</FONT></H1>
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SECURITIES
  EXCHANGE ACT OF 1934</FONT></H1>
  
                                      Date of Report (Date of earliest event reported): July 10, 2001
  
  
                                                                SCIOS, INC.
                                                 _________________________________________
                                            (Exact Name of Registrant as Specified in Charter)
  
  
                Delaware__                                0-11749                               95-3701481
   --------------------------------------     ---------------------------------         ------------------
      (State or Other Jurisdiction of             (Commission File Number)         (I.R.S. Employer Identification No.)
               Incorporation)
  
  
                                        820 West Maude Avenue, Sunnyvale, CA 94086
                           -------------------------------------------------------
                                   (Address of Principal Executive Offices) (Zip Code)
                                                  (408) 616-8200_
                       ------------------------------------------
                                  (Registrant's telephone number, including area code)
  
                                                        N/A
                             ------------------------------
                              (Former Name or Former Address, if Changed Since Last Report)
  
  
  
  
  
  
  
  <PAGE>
  
  
  <H2 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 5. Other
  Events.</FONT></H2>
  
  <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On July 10, 2001, Scios
  Inc., announced that it has received a letter from the U.S. Food and Drug
  Administration stating that the Natrecor&#174; (nesiritide) New Drug Application
  is approvable. For additional information, refer to the press release attached
  as an exhibit to this Current Report on Form 8-K. The contents of the press
  release are incorporated by reference herein. </FONT></P>
  
  Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.
  
  (c)               Exhibits
  
                    The following exhibits are filed as part of this Report:
  
                    No.      Exhibit
                    ---      -------
                    99.1     Press Release dated July 10th, 2001
  
  
  
  
  
  <PAGE>
  
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES</FONT></H1>
  
           Pursuant to the  requirements of the Securities  Exchange Act of 1934, the registrant has duly caused this report to be signed
  on its behalf by the undersigned hereunto duly authorized.
  
                                              SCIOS, INC.
  
  
                                              By:               /s/  John H. Newman____
                                                       --------------------------------
                                                       John H. Newman
                                                       Senior Vice President, General Counsel and Secretary
  
  
  Date:  July 12th, 2001
  
  
  
  <PAGE>
  
  
  <H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT INDEX</FONT></H1>
  
  No.      Exhibit
  ---      -------
  99.1     Press Release dated July 10th, 2001
  
  
  <PAGE>
  
  
  
                                                                                                           Exhibit 99.1
                                                                                                           ------------
  
  Contact:
  --------
  David Gryska, Scios Inc. (408) 616-8325 (investors)
  Ed Bisno, Edelman Public Relations (212) 704-8212 (investors)
  Michelle Choi, Edelman Public Relations (212) 704-4580 (media)
  
  
   Scios Receives Natrecor Approvable Letter
  
  
  
  <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=TOP>
  <TD WIDTH=5%>&nbsp;</TD>
  <TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
  SUNNYVALE,
  CA, July 10, 2001 &#150; Scios Inc. (Nasdaq: SCIO) announced today that it has
  received a letter from the U.S. Food and Drug Administration (FDA) stating that
  the Natrecor<SUP>&#174; </SUP>(nesiritide) New Drug Application (NDA) is
  approvable. Scios has developed Natrecor as an intravenous treatment for
  patients with acutely decompensated congestive heart failure (CHF).</FONT></TD>
  </TR>
  </TABLE>
  <BR>
  
  <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=TOP>
  <TD WIDTH=5%>&nbsp;</TD>
  <TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
  The
  approvable letter is the official communication from the FDA that the agency is
  prepared to approve the NDA following finalization of Natrecor labeling and
  completion of a pre-approval inspection. The FDA&#146;s Cardiovascular and Renal
  Drugs Advisory Committee unanimously recommended approval of Natrecor for the
  treatment of acute CHF on May 25, 2001.</FONT></TD>
  </TR>
  </TABLE>
  <BR>
  
  <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=TOP>
  <TD WIDTH=5%>&nbsp;</TD>
  <TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
  &#147;We
  are delighted to receive the approvable letter and are working closely with the
  FDA to complete the final steps to approval,&#148; said Richard B. Brewer,
  Scios&#146; president and chief executive officer. When approved by the FDA,
  Natrecor will become the first new treatment for acutely decompensated CHF in
  more than a decade. Natrecor is a recombinant form of B-type natriuretic peptide
  (BNP), and would become the first natriuretic peptide product available as a
  therapeutic in the United States. Human BNP is a naturally occurring hormone in
  the body that aids healthy functioning of the heart. Roughly five million
  Americans suffer from heart failure, with 550,000 new cases diagnosed each year.
  There are approximately one million hospitalizations each year in the United
  States due to acute CHF.</FONT></TD>
  </TR>
  </TABLE>
  <BR>
  
   Conference Call
  
  <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=TOP>
  <TD WIDTH=5%>&nbsp;</TD>
  <TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
  Scios
  executives will host a conference call and live audio webcast at 2:30 p.m. PDT
  (5:30 p.m. EDT) on Tuesday, July 10 to discuss Natrecor and its next steps to
  commercialization. To participate, please call (800) 474-8920 at least 5 minutes
  prior to start time. To access the live webcast, please log on to
  <U>www.sciosinc.com</U> approximately fifteen minutes prior to the call to
  register, download and install any necessary audio software. A replay of the
  live webcast will be made available on the Scios website shortly after the
  conclusion of the call through July 18, 2001. A replay of the telephonic
  conference call will be available by dialing (888) 203-1112, access code 713213.
  The telephone replay will be available through July 18, 2001. <B>Scios Inc.</B></FONT></TD>
  </TR>
  </TABLE>
  <BR>
  
  <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=TOP>
  <TD WIDTH=5%>&nbsp;</TD>
  <TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
  Scios
  is a biopharmaceutical company developing novel treatments for cardiovascular
  and inflammatory disease. The Company&#146;s disease-based technology platform
  integrates expertise in protein biology with computational and medicinal
  chemistry to identify novel targets and rationally design small molecule
  compounds for large markets with unmet medical needs.</FONT></TD>
  </TR>
  </TABLE>
  <BR>
  
  <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=TOP>
  <TD WIDTH=5%>&nbsp;</TD>
  <TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
  The
  statements in this press release that are not historical facts are
  forward-looking statements that involve risks and uncertainties. These include
  uncertainties associated with the timing of the final approval of Natrecor, as
  well as other risks detailed from time to time in the reports filed by Scios
  with the SEC, including the company&#146;s annual report on form 10-K for the
  year ended December 31, 2000 and form 10-Q for the quarter ended March 31, 2001.</FONT></TD>
  </TR>
  </TABLE>
  <BR>
  </BODY>
  </HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "k8sciosinc71001.html", "description": "SCIOS INC 8-K", "secsgml_size_bytes": 8685}]
metadata_filer: {"company-data": {"conformed-name": "SCIOS INC", "cik": "0000726512", "assigned-sic": "2834", "irs-number": "953701481", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11749", "film-number": "1680339"}, "business-address": {"street1": "820 W MAUDE AVE", "city": "SUNNYVALE", "state": "CA", "zip": "94086", "phone": "4086168200"}, "mail-address": {"street1": "820 W MAUDE AVENUE", "city": "SUNNYVALE", "state": "CA", "zip": "94085"}, "former-company": [{"former-conformed-name": "SCIOS INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA BIOTECHNOLOGY INC", "date-changed": "19920302"}]}
text: 6
  SECURITIES
  AND EXCHANGE COMMISSION
  WASHINGTON,
  D.C. 20549
  FORM 8-K
  CURRENT
  REPORTPURSUANT
  TO SECTION 13 OR 15(d) OF THE
  SECURITIES
  EXCHANGE ACT OF 1934
  Date of Report (Date of earliest event reported): July 10, 2001
  
                                                                SCIOS, INC.
                                                 _________________________________________
                                            (Exact Name of Registrant as Specified in Charter)
  
                Delaware__                                0-11749                               95-3701481
   --------------------------------------     ---------------------------------         ------------------
      (State or Other Jurisdiction of             (Commission File Number)         (I.R.S. Employer Identification No.)
               Incorporation)
  
                                        820 West Maude Avenue, Sunnyvale, CA 94086
                           -------------------------------------------------------
                                   (Address of Principal Executive Offices) (Zip Code)
                                                  (408) 616-8200_
                       ------------------------------------------
                                  (Registrant's telephone number, including area code)
  
                                                        N/A
                             ------------------------------
                              (Former Name or Former Address, if Changed Since Last Report)
  Item 5. Other
  Events.
  On July 10, 2001, Scios
  Inc., announced that it has received a letter from the U.S. Food and Drug
  Administration stating that the Natrecor® (nesiritide) New Drug Application
  is approvable. For additional information, refer to the press release attached
  as an exhibit to this Current Report on Form 8-K. The contents of the press
  release are incorporated by reference herein.
  Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.
  
  (c)               Exhibits
  
                    The following exhibits are filed as part of this Report:
  
                    No.      Exhibit
                    ---      -------
                    99.1     Press Release dated July 10th, 2001
  SIGNATURES
  Pursuant to the  requirements of the Securities  Exchange Act of 1934, the registrant has duly caused this report to be signed
  on its behalf by the undersigned hereunto duly authorized.
  
                                              SCIOS, INC.
  
                                              By:               /s/  John H. Newman____
                                                       --------------------------------
                                                       John H. Newman
                                                       Senior Vice President, General Counsel and Secretary
  
  Date:  July 12th, 2001
  EXHIBIT INDEX
  No.      Exhibit
  ---      -------
  99.1     Press Release dated July 10th, 2001
  Exhibit 99.1
                                                                                                           ------------
  
  Contact:
  --------
  David Gryska, Scios Inc. (408) 616-8325 (investors)
  Ed Bisno, Edelman Public Relations (212) 704-8212 (investors)
  Michelle Choi, Edelman Public Relations (212) 704-4580 (media)
  
   Scios Receives Natrecor Approvable Letter
  SUNNYVALE,
  CA, July 10, 2001 – Scios Inc. (Nasdaq: SCIO) announced today that it has
  received a letter from the U.S. Food and Drug Administration (FDA) stating that
  the Natrecor
  ®
  (nesiritide) New Drug Application (NDA) is
  approvable. Scios has developed Natrecor as an intravenous treatment for
  patients with acutely decompensated congestive heart failure (CHF).
  The
  approvable letter is the official communication from the FDA that the agency is
  prepared to approve the NDA following finalization of Natrecor labeling and
  completion of a pre-approval inspection. The FDA's Cardiovascular and Renal
  Drugs Advisory Committee unanimously recommended approval of Natrecor for the
  treatment of acute CHF on May 25, 2001.
  "We
  are delighted to receive the approvable letter and are working closely with the
  FDA to complete the final steps to approval," said Richard B. Brewer,
  Scios' president and chief executive officer. When approved by the FDA,
  Natrecor will become the first new treatment for acutely decompensated CHF in
  more than a decade. Natrecor is a recombinant form of B-type natriuretic peptide
  (BNP), and would become the first natriuretic peptide product available as a
  therapeutic in the United States. Human BNP is a naturally occurring hormone in
  the body that aids healthy functioning of the heart. Roughly five million
  Americans suffer from heart failure, with 550,000 new cases diagnosed each year.
  There are approximately one million hospitalizations each year in the United
  States due to acute CHF.
  Conference Call
  Scios
  executives will host a conference call and live audio webcast at 2:30 p.m. PDT
  (5:30 p.m. EDT) on Tuesday, July 10 to discuss Natrecor and its next steps to
  commercialization. To participate, please call (800) 474-8920 at least 5 minutes
  prior to start time. To access the live webcast, please log on to
  www.sciosinc.com
  approximately fifteen minutes prior to the call to
  register, download and install any necessary audio software. A replay of the
  live webcast will be made available on the Scios website shortly after the
  conclusion of the call through July 18, 2001. A replay of the telephonic
  conference call will be available by dialing (888) 203-1112, access code 713213.
  The telephone replay will be available through July 18, 2001.
  Scios Inc.
  Scios
  is a biopharmaceutical company developing novel treatments for cardiovascular
  and inflammatory disease. The Company's disease-based technology platform
  integrates expertise in protein biology with computational and medicinal
  chemistry to identify novel targets and rationally design small molecule
  compounds for large markets with unmet medical needs.
  The
  statements in this press release that are not historical facts are
  forward-looking statements that involve risks and uncertainties. These include
  uncertainties associated with the timing of the final approval of Natrecor, as
  well as other risks detailed from time to time in the reports filed by Scios
  with the SEC, including the company's annual report on form 10-K for the
  year ended December 31, 2000 and form 10-Q for the quarter ended March 31, 2001.